Cell News and Research

RSS

UCLA scientist develops new way to map cellular metabolism

Nutrition advice is everywhere. Eat more protein. Cut back on sugar. Get more fiber. But beneath all that advice is a surprisingly basic gap in our understanding: Scientists still have a limited view of what happens when specific nutrients reach individual cells inside the body.

6 Oct 2026

Global scientific collaboration brings hope to lobular breast cancer patients

Every October, Breast Cancer Awareness Month brings people around the world together under the pink ribbon to raise awareness, encourage early detection, support patients and fund research.

6 Oct 2026

UCLA researcher wins the 2026 Albany Prize for revolutionary cancer therapy discoveries

Dr. Dennis Slamon, a pioneering oncologist and researcher at the UCLA Health Jonsson Comprehensive Cancer Center, has been awarded the 2026 Albany Prize for discoveries that transformed the understanding and treatment of cancer.

6 Oct 2026

Scientists discover a novel strategy to unmask cancer cells in high-risk neuroblastoma

High-risk neuroblastoma is one of the most aggressive forms of solid tumors affecting children, originating in the nervous system.

6 Oct 2026

Novel peptide approach reduces chronic neuropathic pain in mice

Understanding and treating chronic neuropathic pain has remained challenging due to its complex nature. New research from the lab of Clifford Woolf, MB, BCh, PhD, at Boston Children's Hospital's FM Kirby Neurobiology Center describes a novel approach for reducing pain by disrupting interactions within pain-sensing nerve cells called nociceptors

6 Oct 2026

Mini-GRID radiotherapy limits cellular senescence in glioma models

A new research paper was recently published in Volume 18 of Aging, titled "Spatially fractionated mini-GRID radiotherapy differentially modulates radiation-induced senescence in murine glioma and normal cells."

6 Oct 2026

SGLT2 inhibitors reduce inflammatory cells linked to heart disease

For the first time in a human trial, a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, already known for their weight loss and glucose lowering benefits, has been shown to also reduce inflammatory cells in the blood known to cause cardiovascular disease.

6 Oct 2026

C-Path and University of Arizona collaborate to investigate cellular mechanisms of Parkinson's disease in women

Critical Path Institute (C-Path) today announced a research collaboration with the University of Arizona to investigate the cellular mechanisms that drive Parkinson's disease in women.

6 Oct 2026

Experimental cancer drug works differently than researchers originally thought

A cancer drug currently being tested in patients may have entered clinical trials based on an incorrect understanding of how it works, according to a new study led by the University of Sydney in collaboration with Goethe University, Oxford University and the Institute of Cancer Research, London.

6 Oct 2026

Human dental pulp stem cell secretome boosts stroke recovery

Ischemic stroke can leave lasting neurological damage after the initial vascular event, with oxidative stress, neuroinflammation, neuronal death, and disruption of neural connectivity contributing to impaired recovery.

6 Oct 2026

Study identifies spatial niche as key to gastric cancer initiation

Early gastric cancer (EGC) represents the most critical yet biologically least understood stage in gastric carcinogenesis.

6 Oct 2026

Short-term vaping exposure injures deep lung tissue and immunity

Just days of e-cigarette vapor exposure can injure the lungs' most delicate tissue and leave it more vulnerable to viral infection, according to a study led by National Jewish Health researchers and published in JCI Insight.

6 Oct 2026

Mount Sinai adopts automated data integration for oncology clinical trials

The Mount Sinai Tisch Cancer Center has transitioned its electronic health record (EHR)-to-clinical trial data integration technology from pilot to routine use across its cancer research program.

6 Oct 2026

Model tracks invisible C. diff transmission in hospital cancer units

In a new study, researchers modeled the transmission of Clostridioides difficile (C. diff) infections among patients in hospital cancer units.

6 Oct 2026

Cigarette smoke alters lung stem cells to drive specific cancers

Chronic exposure to cigarette smoke may reprogram different populations of lung stem cells, which maintain and repair lung tissue, in ways that make them vulnerable to specific cancer-causing gene alterations and ultimately helps determine the type of lung cancer that develops.

6 Oct 2026

Managing misfolded proteins to prevent Parkinson’s disease

The protein alpha-synuclein is abundant in healthy brains and plays an important role in enabling communication between nerve cells. However, under certain conditions, misfolded alpha-synuclein proteins can accumulate into toxic clumps inside neurons

6 Oct 2026

New insights into fetal DNA could improve prenatal testing

Understanding how fetal DNA travels in a pregnant woman’s blood could unlock the next generation of prenatal screening, according to a new paper published in Science Advances today.

6 Oct 2026

Terumo Blood and Cell Technologies partners with TrAMPoline Pharma to automate TIL therapy manufacturing for solid tumors

Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company advancing blood- and cell-based therapies worldwide, has entered a research collaboration with TrAMPoline Pharma and Eduardo Davila, PhD, at the University of Colorado to develop an automated manufacturing approach for tumor-infiltrating lymphocyte (TIL) therapies targeting solid tumors.

6 Oct 2026

Before the first bite: A missing gut protein may set the stage for peanut allergy

For most people, a peanut butter sandwich poses no threat. But for the roughly 1.6 million children in the United States with peanut allergy, exposure can trigger a life-threatening reaction.

6 Oct 2026

Phase III trial tests MRD-guided treatment for patients with ER-positive/HER2-negative breast cancer

Alliance Foundation Trials, LLC (AFT), a national leader in conducting innovative, practice-changing cancer clinical trials, and Natera, Inc., a global leader in cell-free DNA and precision medicine, today announced the launch of AFT-70 NAVIGATE, a randomized phase III trial evaluating a novel molecular residual disease (MRD)-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cancer.

5 Oct 2026